Gland Pharma names Srinivas Sadu as Executive Chairman, CEO
Hyderabad: Gland Pharma Limited, a generic injectable-focused
pharmaceutical company, has announced that Srinivas Sadu, the incumbent Managing Director (MD) and CEO, has been appointed as Executive Chairman and CEO of the company, effective June 10, 2024.
He holds master’s degree in Industrial Pharmacy from Long Island University, New York; MBA from University of Maryland, Baltimore; and postgraduate certification in Finance and Management from London School of Business and Finance. He has over 23 years of experience in business development, manufacturing operations, supply chain management and strategic planning. He has been associated with Gland Pharma Limited for the last 22 years. He joined the Company as the general manager – exports in 2000, and was elevated to position of senior general manager in 2002, vice president in 2003, director in 2005, and chief operating officer in 2011. He was appointed as the MD and CEO with effect from April 25, 2019. Under his leadership, the Company has consistently witnessed growth, both in terms of revenue and profits, while expanding across all geographies.
Read also: USFDA approves Gland Pharma Plerixafor Injection
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer
of small-volume liquid parenteral products to become growing injectable-focused
companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia,
India, and other markets. It operates primarily under a business-to-business (B2B) model and develops, manufactures, and markets sterile injectables. It has a wide range of injectables,
including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic
solutions.
Read also: Gland Pharma bags USFDA nod for amyotrophic lateral sclerosis injection Edaravone
